Related Experiment Video
Updated: May 23, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Pyrazolopyrimidines: A Promising Frontier in Cancer Treatment-Reviewing Their Potential as Inhibitors of
Ahmed M Abdelhamed1, Amira A Helwa1, Hanan H Kadry2
1Pharmaceutical Organic Chemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST), 6th of October City, Egypt.
Abstract:
Pyrazolopyrimidine derivatives have emerged as potent inhibitors targeting a broad spectrum of kinases, particularly serine/threonine kinases (STK). This review provides a comprehensive overview of the structural modifications and pharmacological relevance of pyrazolopyrimidine compounds in the realm of kinase inhibition. Specifically, the focus is placed on their inhibitory action against STK, key players in cell signaling and potential therapeutic targets in various diseases, especially cancer. The structure-activity relationship (SAR) of these derivatives highlights the importance of specific substituents in enhancing inhibitory activity, and pyrazolopyrimidine derivatives have shown promising inhibitory activity against certain STK. Challenges remain, including issues related to drug resistance, off-target effects, and potential toxicity. Future research is geared toward designing more selective derivatives with improved pharmacokinetic properties and reduced side effects.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle
Treatment Resistant Cancers

